Vancomycin removal during low-flux and high-flux extended daily hemodialysis in critically ill septic patients

Biomedical Papers

Volumn 156, Issue 4, 2012, Pages 342-347

  Petejova, Nadezda ^a   Martinek, Arnost ^a   Zahalkova, Jana ^b,c   Duricova, Jana ^a   Brozmanova, Hana ^a   Urbanek, Karel ^d   Grundmann, Milan ^a   Kacirova, Ivana ^a  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c Sternberk Hospital   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Acute kidney injury; Hemodialysis; High flux; Low flux; Polysulphone membrane; Sepsis; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ARTICLE; HUMAN; MALE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SEPSIS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; SEPSIS; VANCOMYCIN;

EID: 84872023378     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.002     Document Type: Article

References (29)

1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP.The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995;273:117-23.
2. Langenberg C, Bellomo R, May C, Wan L, Egi M, Morgera S. Renal blood flow in sepsis. Crit Care 2005;9:R363-74.
3. Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Oudemans-van Straaten H, Ronco C, Kellum JA. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med 2007;33:1563-70.
4. Rabindranath K, Adams J, Macleod AM, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev 2007;18:CD003773.
5. Bellomo R, Palevsky PM, Bagshaw SM, Gibney N, McAlister FA, Honore PM, Joannes-Boyau O, Prowle J, Haase M, Cruz DN, Ronco C. Recent trials in critical care nephrology. Contrib Nephrol 2010;165:299-309.
6. McKenzie C.Antibiotic dosing in critical illness. J Antimicrob Chemother 2011;66 Suppl 2:ii25-31.
7. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm 2009;66:82-98.
8. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25:433-7.
9. Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clin Inf Dis 2006;42:S35-9.
10. Cunha BA, Quintiliani R, Deglin JM, Izard MW, Nightingale CH. Pharmacokinetics of vancomycin in anuria. Rev Infect Dis http://www.ncbi.nlm.nih.gov/ 1981;3 suppl:S269-72.
11. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6.
12. Lindholm DD, Murray JS. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med 1966;274:1047-51.
13. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA. Pharmacokinetics of vancomycin when administered during high flux hemodialysis. Clin Nephrolhttp://www.ncbi.nlm.nih.gov/ 1998;50:51-5.
14. Touchette MA, Patel RV, Anandan JV, Dumler F, Zarowitz BJ. Vancomycin removal by high-flux polysulfone hemodialysis membranes in critically ill patients with end-stage renal disease. Am J Kidney Dis 1995;26:469-74.
15. Stamatakis MK, Schreiber JM, Slain D, Gunel E. Vancomycin administration during dialysis with low-flux polysulfone membranes: traditional versus a supplemental dosage regimen. Am J Health Syst Pharm 2003;60:1564-8.
16. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996;50:929-36.
17. Keller F, Hörstensmeyer C, Looby M, Borner K, Pommer W, Erdmann K, Giehl M. Vancomycin dosing in haemodialysis patients and Bayesian estimate of individual pharmacokinetic parameters. Int J Artif Organs 1994;17:19-26.
18. Zoer J, Schrander-van der Meer AM, van Dorp WT. Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes. Pharm World Sci 1997;19:191-6.
19. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 2005;46:681-7.
20. Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller PD, Olsen KM. Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients. Crit Care Med 2011;39:560-70.
21. Lanese DM, Alfrey PS, Molitoris BA. Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989;35:1409-12.
22. Mason NA, Neudeck BL, Welage LS, Patel JA, Swartz RD. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration. Clin Nephrol 2003;60:96-104.
23. Kielstein JT, Czock D, Schöpke T, Hafer C, Bode-Böger SM, Kuse E, Keller F, Fliser D. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006;34:51-6.
24. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int 2010;77:760-4.
25. Panais R, Hirsch DJ, Dipchand C, Storsley L, Finkle SN. A protocolized approach to vancomycin dosing in conventional hemodialysis. J Nephrol 2010;23:569-74.
26. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991;50:688-94.
27. Launay-Vacher V, Izzedine H, Mercadal L, Deray G. Clinical review: use of vancomycin in haemodialysis patients. Crit Care 2002;6:313-16.
28. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, Maroni BJ. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int 1994;45:232-7.
29. Zahálková J, Strojil J, Petejová N, Urbánek K, Grundmann M, Kacířová I. Dávkovaní vankomycinu při kontinuální náhradě funkce ledvin. Klin Farmakol Farm 2011;25:116-21.